Aarti Drugs Files FY26 Annual Report and AGM Notice

Aarti Drugs Ltd has filed its Annual Report for the Financial Year 2025-26, along with the notice for its 41st Annual General Meeting (AGM) scheduled for September 26, 2026. The report highlights the company's strategic investments translating into operational progress, including the commencement of commercial production at the Sayakha facility, increased Salicylic Acid production at Tarapur, and expanded global regulatory approvals (USFDA, UK MHRA, EU GMP) which contributed 73% of revenues. The company also noted progress on its solar power project and a record-low debt-to-equity ratio, positioning it for future growth despite market challenges.